HopeStage
Back to all studies
CompletedNCT02611752

Repeated-Dose Opioid Blockade With CAM2038

About this titleRead the official source — NCT02611752
Medication studyAges 18–55United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
Overland Park and 2 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2015
Recruitment status
Completed
Enrollment listed in the registry
47
Sponsor
Braeburn Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT02611752
Official title
Show the full official title

A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Overland Park · Lexington · New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Braeburn Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including CAM2038.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies